These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Oh ST; Gotlib J Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983 [TBL] [Abstract][Full Text] [Related]
4. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hobbs GS; Rozelle S; Mullally A Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391 [TBL] [Abstract][Full Text] [Related]
5. JAK2 inhibition for the treatment of hematologic and solid malignancies. Harry BL; Eckhardt SG; Jimeno A Expert Opin Investig Drugs; 2012 May; 21(5):637-55. PubMed ID: 22493978 [TBL] [Abstract][Full Text] [Related]
6. New JAK2 inhibitors for myeloproliferative neoplasms. Quintás-Cardama A; Verstovsek S Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147 [TBL] [Abstract][Full Text] [Related]
7. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Tefferi A Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973 [TBL] [Abstract][Full Text] [Related]
8. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459 [TBL] [Abstract][Full Text] [Related]
9. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Valentino L; Pierre J Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581 [TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy. Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. Meyer SC Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392 [TBL] [Abstract][Full Text] [Related]
16. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Levine RL; Wernig G Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066 [TBL] [Abstract][Full Text] [Related]
17. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms. Bhagwat N; Levine RL; Koppikar P Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175 [TBL] [Abstract][Full Text] [Related]
18. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172 [TBL] [Abstract][Full Text] [Related]
19. Mining for JAK-STAT mutations in cancer. Constantinescu SN; Girardot M; Pecquet C Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658 [TBL] [Abstract][Full Text] [Related]
20. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Rosenthal A; Mesa RA Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]